AKER BIOMARINE 14 July 2022 :Aker BioMarine ASA ("Aker BioMarine " or "the company") reports revenues ofUSD 73 million and Adjusted EBITDA ofUSD 21 million for the second quarter 2022. "Aker BioMarine delivers good profitability in the quarter, specially driven by high sales volumes and prices for Qrill Aqua. The company has also improved krill harvesting, and so far this year Antarctic production of krill meal is 39,000 tons, 13% above last year. The Superba krill oil sales organization is strengthened in all geographies and will execute on the upgraded pipeline to deliver growth. We reiterate our financial targets for the full year 2022", saidMatts Johansen , CEO ofAker BioMarine . Highlights second quarter: - Revenues ofUSD 73 million , on par with the same quarter last year - Adjusted EBITDA ofUSD 21 million , up 11% from the same quarter last year - Net profit ofUSD 15 million , up fromUSD -3 million the same quarter last year - Sales in the Ingredients segment, up 8% from same quarter last year - Sales in the Brands segment, down 16% from same quarter last year - Offshore production volume at 16,500 tons, the highest second quarter ever and up 19% from same quarter last yearAker BioMarine reiterates its targets for 2022 with a sales growth of between 20-25%, and an Adjusted EBITDA margin of 20-25%. At09:00 CET today, the management hosts a webcast. Following the presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com. The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor. A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address. For further information, please contactCarl Christian Bachke , Investor Relations Mobile: +47 909 808 48 Email: carl.bachke@akerbiomarine.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
Click here for more information
© Oslo Bors ASA, source
